News

The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded $1.5 million to Oryzon Genomics to support expanding an ongoing Phase 2a trial assessing the potential of vafidemstat (ORY-2001) in patients with mild to moderate Alzheimer’s disease to the United States. The double-blind, placebo-controlled trial (2017-004893-32), called…

Alzheimer’s oral therapy candidate PRI-002, being developed by Priavoid, has proven safe for human use in healthy volunteers during a Phase 1 clinical trial. These positive trial results provide important evidence that supports progressing…

The U.S. Food and Drug Administration has approved Neuronascent’s investigational new drug (IND) application for NNI-362, its therapy candidate for Alzheimer’s disease, allowing it to move ahead with a Phase 1a clinical trial, the company announced. The first-in-human trial will evaluate the safety of NNI-362 in…

Elenbecestat and BAN2401, two potential anti-amyloid therapies, were selected by the Alzheimer’s Clinical Trials Consortium (ACTC) to be evaluated in clinical studies aiming to prevent progression to early stages of Alzheimer’s disease.

High blood levels of primary fatty acid amides (PFAMS), a class of fatty molecules involved in sleep and movement control, are associated with increased accumulation of beta-amyloid protein in the cerebrospinal fluid of patients with Alzheimer’s disease, a study finds. Researchers believe that this class of fatty…

A new program called the Dementia Friendly Hospital Initiative is set to be launched in North Carolina to raise awareness among healthcare providers on how patients with Alzheimer’s disease and dementia experience care interventions and how to meet their needs. Led by the University of North Carolina School of…

An online program that teaches how to focus on positive emotions can help caregivers of family members with dementia to cope better with stress, and reduce their depression and anxiety symptoms, results from a clinical study suggest. The six-week skill-building intervention, called Life Enhancing Activities for…

Tetra Discovery Partners is launching a Phase 2 clinical trial for BPN14770 — found to improve working memory in older patients in earlier trials — as a treatment for people with early stage Alzheimer’s disease. The trial, called PICASSO AD (NCT03817684), is recruiting in about 60 clinical…

Adding memantine to a cholinesterase inhibitor can significantly ease certain neuropsychiatric symptoms, including psychosis and troubling motor or nighttime behavior, in people with moderate-to-severe Alzheimer’s disease, according to pooled data from three Phase 3 clinical trials. But it was not seen to be of any benefit in addressing problems of…

Cumbersome security procedures, rising airfares, and shrinking legroom have made commercial air travel difficult enough these days — even for healthy passengers. Imagine how much harder it is for patients with rare diseases who must get to doctors’ appointments or clinical trials that are hundreds of miles away from home.